Alzheimer’s Disease (AD) is the most prevalent neurodegenerative disorder in The United States affecting approximately 5.4 million Americans. AD is characterized by a progressive loss in memory and as well as a decline in the ability to learn that is associated with neuronal death. Currently, no treatment has been developed to fully cure or prevent the progression of dementia that is associated with AD.
Northern California Research is conducting a phase-2 clinical research study to evaluate the efficacy and safety of the study medication AR1001 for potential treatment in patients with mild to moderate Alzheimer’s disease. This medication is given via IV infusion. Participants must have a diagnosis of probable Alzheimer’s Disease and a Caregiver who can assist the patient through the entire duration of the study. *Must have been diagnosed by MRI or CT scan*
The trial doctor will review other eligibility criteria with you. This study is 7 weeks long and includes 7 office visits. All trial-related visits, tests, and medications will be provided to you at no cost. In addition, reimbursement for trial-related time and travel may be provided.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03625622